News blog
Merck shutters RNAi research facility
Less than five years after betting $1.1 billion on the power of RNA-interference (RNAi) to treat disease, pharmaceutical powerhouse Merck is shutting down the San Francisco research facility it acquired when it purchased Sirna Therapeutics, a biotechnology firm that specialized in RNAi, in 2006.
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells